HAEM5:Systemic EBV-positive T-cell lymphoma of childhood - Revision history

Richard.Glen: Section title fix

2026-04-21T18:36:21Z

Section title fix

← Older revision		Revision as of 13:36, 21 April 2026
Line 96:		Line 96:
	\|}		\|}

	== Gene Mutations (SNV/~~INDELS~~) ==		== Gene Mutations (SNV/INDEL) ==
	Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" />		Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" />
	* ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref>{{Cite journal\|last=Asmussen\|first=Anders\|last2=Quintanilla-Martinez\|first2=Leticia\|last3=Larsen\|first3=Martin\|last4=Fagerberg\|first4=Christina\|last5=Bækvad-Hansen\|first5=Marie\|last6=Juul\|first6=Maja Bech\|last7=Rewers\|first7=Kate\|last8=Raaschou-Jensen\|first8=Klas\|last9=Barnkob\|first9=Mike Bogetofte\|date=2024-01\|title=Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case\|url=https://pubmed.ncbi.nlm.nih.gov/37871127\|journal=Leukemia & Lymphoma\|volume=65\|issue=1\|pages=118–122\|doi=10.1080/10428194.2023.2264425\|issn=1029-2403\|pmid=37871127}}</ref>		* ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref>{{Cite journal\|last=Asmussen\|first=Anders\|last2=Quintanilla-Martinez\|first2=Leticia\|last3=Larsen\|first3=Martin\|last4=Fagerberg\|first4=Christina\|last5=Bækvad-Hansen\|first5=Marie\|last6=Juul\|first6=Maja Bech\|last7=Rewers\|first7=Kate\|last8=Raaschou-Jensen\|first8=Klas\|last9=Barnkob\|first9=Mike Bogetofte\|date=2024-01\|title=Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case\|url=https://pubmed.ncbi.nlm.nih.gov/37871127\|journal=Leukemia & Lymphoma\|volume=65\|issue=1\|pages=118–122\|doi=10.1080/10428194.2023.2264425\|issn=1029-2403\|pmid=37871127}}</ref>

Sumire.Kitahara: /* Gene Mutations (SNV/INDELS) */

2026-02-15T03:45:28Z

Gene Mutations (SNV/INDELS)

← Older revision		Revision as of 22:45, 14 February 2026
Line 98:		Line 98:
	== Gene Mutations (SNV/INDELS) ==		== Gene Mutations (SNV/INDELS) ==
	Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" />		Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" />
	* ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref ~~name~~=":2" />		* ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref>{{Cite journal\|last=Asmussen\|first=Anders\|last2=Quintanilla-Martinez\|first2=Leticia\|last3=Larsen\|first3=Martin\|last4=Fagerberg\|first4=Christina\|last5=Bækvad-Hansen\|first5=Marie\|last6=Juul\|first6=Maja Bech\|last7=Rewers\|first7=Kate\|last8=Raaschou-Jensen\|first8=Klas\|last9=Barnkob\|first9=Mike Bogetofte\|date=2024-01\|title=Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case\|url=https://pubmed.ncbi.nlm.nih.gov/37871127\|journal=Leukemia & Lymphoma\|volume=65\|issue=1\|pages=118–122\|doi=10.1080/10428194.2023.2264425\|issn=1029-2403\|pmid=37871127}}</ref>
	* Mutations in ''KMT2D'', ''MFHAS1'', ''STAT3'', ''EP300'', ''ITPKB'', ''DDX3X'', ''NOTCH1'', ''NOTCH2'', and ''TET2'' (amongst others) have also been reported		* Mutations in ''KMT2D'', ''MFHAS1'', ''STAT3'', ''EP300'', ''ITPKB'', ''DDX3X'', ''NOTCH1'', ''NOTCH2'', and ''TET2'' (amongst others) have also been reported
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 115:		Line 115:
	\|N/A		\|N/A
	\|N/A		\|N/A
	\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.		\|}

	== Epigenomic Alterations ==		== Epigenomic Alterations ==
	N/A		N/A
Line 162:		Line 161:

	Prior Author(s): Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA		Prior Author(s): Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA


	''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.<center>		''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.<center>

Sumire.Kitahara: /* References */

2026-02-15T03:41:42Z

References

← Older revision		Revision as of 22:41, 14 February 2026
Line 156:		Line 156:
	== References ==		== References ==
	<references />		<references />
	~~<center><center>~~
	~~<center><center>~~
	~~<center><center>~~
	~~<center>~~
	~~<br />~~






	== Notes ==		== Notes ==
			[[Category:HAEM5]]
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

Line 173:		Line 164:


	''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.		''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.<center>
			<center>
	[[Category:HAEM5]]		[[Category:HAEM5]]
			[[Category:DISEASE]]
			[[Category:Diseases S]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases S]]		[[Category:Diseases S]]

Sumire.Kitahara at 03:36, 15 February 2026

2026-02-15T03:36:48Z

← Older revision		Revision as of 22:36, 14 February 2026
Line 161:		Line 161:
	<center>		<center>
	<br />		<br />




Line 171:		Line 173:


	~~<nowiki>*</nowiki>~~''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.~~<center><center>~~		''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.
	~~<center><center>~~
	~~<center><center>~~
	~~<center>~~
	~~<center><center>~~
	~~<center><center>~~
	~~<center><center>~~
	~~<center>~~
	[[Category:HAEM5]]		[[Category:HAEM5]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases S]]		[[Category:Diseases S]]

Sumire.Kitahara at 03:35, 15 February 2026

2026-02-15T03:35:19Z

← Older revision		Revision as of 22:35, 14 February 2026
Line 161:		Line 161:
	<center>		<center>
	<br />		<br />




	== Notes ==		== Notes ==
			<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

			Prior Author(s): Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA


			<nowiki>*</nowiki>''Citation of this Page'': Miller K. “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.<center><center>
			<center><center>
			<center><center>
			<center>
	<center><center>		<center><center>
	<center><center>		<center><center>
	<center><center>		<center><center>
	<center>		<center>
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	~~Prior Author(s): Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA~~



	<nowiki>*</nowiki>''Citation of this Page'': “Systemic EBV-positive T-cell lymphoma of childhood”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Systemic_EBV-positive_T-cell_lymphoma_of_childhood</nowiki>.
	[[Category:HAEM5]]		[[Category:HAEM5]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases S]]		[[Category:Diseases S]]

Sumire.Kitahara at 03:32, 15 February 2026

2026-02-15T03:32:08Z

Show changes

Karin.Miller: /* Gene Rearrangements */

2025-11-20T17:46:02Z

Gene Rearrangements

← Older revision		Revision as of 12:46, 20 November 2025
Line 39:		Line 39:

	==Gene Rearrangements==		==Gene Rearrangements==
	Monoclonal T-cell receptor gene rearrangements in most cases.<ref name=":1">{{Cite journal\|last=Quintanilla-Martinez\|first=L.\|last2=Kumar\|first2=S.\|last3=Fend\|first3=F.\|last4=Reyes\|first4=E.\|last5=Teruya-Feldstein\|first5=J.\|last6=Kingma\|first6=D. W.\|last7=Sorbara\|first7=L.\|last8=Raffeld\|first8=M.\|last9=Straus\|first9=S. E.\|date=2000-07-15\|title=Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome\|url=https://pubmed.ncbi.nlm.nih.gov/10887104\|journal=Blood\|volume=96\|issue=2\|pages=443–451\|issn=0006-4971\|pmid=10887104}}</ref><ref name=":7">{{Cite journal\|last=Coffey\|first=Amy M.\|last2=Lewis\|first2=Annisa\|last3=Marcogliese\|first3=Andrea N.\|last4=Elghetany\|first4=M. Tarek\|last5=Punia\|first5=Jyotinder N.\|last6=Chang\|first6=Chung-Che\|last7=Allen\|first7=Carl E.\|last8=McClain\|first8=Kenneth L.\|last9=Gaikwad\|first9=Amos S.\|date=2019-08\|title=A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America\|url=https://pubmed.ncbi.nlm.nih.gov/31099136\|journal=Pediatric Blood & Cancer\|volume=66\|issue=8\|pages=e27798\|doi=10.1002/pbc.27798\|issn=1545-5017\|pmid=31099136}}</ref> T-cell clonality can also be detected in EBV-associated HLH and other EBV-associated disorders.<ref name=":10">{{Cite journal\|last=Dojcinov\|first=Stefan D.\|last2=Quintanilla-Martinez\|first2=Leticia\|date=2023-01-04\|title=How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders\|url=https://pubmed.ncbi.nlm.nih.gov/36214507\|journal=American Journal of Clinical Pathology\|volume=159\|issue=1\|pages=14–33\|doi=10.1093/ajcp/aqac105\|issn=1943-7722\|pmid=36214507}}</ref>		Monoclonal T-cell receptor gene rearrangements in most cases.<ref name=":1">{{Cite journal\|last=Quintanilla-Martinez\|first=L.\|last2=Kumar\|first2=S.\|last3=Fend\|first3=F.\|last4=Reyes\|first4=E.\|last5=Teruya-Feldstein\|first5=J.\|last6=Kingma\|first6=D. W.\|last7=Sorbara\|first7=L.\|last8=Raffeld\|first8=M.\|last9=Straus\|first9=S. E.\|date=2000-07-15\|title=Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome\|url=https://pubmed.ncbi.nlm.nih.gov/10887104\|journal=Blood\|volume=96\|issue=2\|pages=443–451\|issn=0006-4971\|pmid=10887104}}</ref><ref name=":7">{{Cite journal\|last=Coffey\|first=Amy M.\|last2=Lewis\|first2=Annisa\|last3=Marcogliese\|first3=Andrea N.\|last4=Elghetany\|first4=M. Tarek\|last5=Punia\|first5=Jyotinder N.\|last6=Chang\|first6=Chung-Che\|last7=Allen\|first7=Carl E.\|last8=McClain\|first8=Kenneth L.\|last9=Gaikwad\|first9=Amos S.\|date=2019-08\|title=A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America\|url=https://pubmed.ncbi.nlm.nih.gov/31099136\|journal=Pediatric Blood & Cancer\|volume=66\|issue=8\|pages=e27798\|doi=10.1002/pbc.27798\|issn=1545-5017\|pmid=31099136}}</ref> T-cell clonality can also be detected in EBV-associated HLH and other EBV-associated disorders.<ref name=":10">{{Cite journal\|last=Dojcinov\|first=Stefan D.\|last2=Quintanilla-Martinez\|first2=Leticia\|date=2023-01-04\|title=How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders\|url=https://pubmed.ncbi.nlm.nih.gov/36214507\|journal=American Journal of Clinical Pathology\|volume=159\|issue=1\|pages=14–33\|doi=10.1093/ajcp/aqac105\|issn=1943-7722\|pmid=36214507}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-

Karin.Miller: /* Gene Mutations (SNV/INDELS) */

2025-11-19T22:49:05Z

Gene Mutations (SNV/INDELS)

← Older revision		Revision as of 17:49, 19 November 2025
Line 104:		Line 104:
	* Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" /><ref>{{Cite journal\|last=Saleem\|first=Atif\|last2=Joshi\|first2=Rohan\|last3=Lei\|first3=Li\|last4=Lezama\|first4=Lhara\|last5=Raghavan\|first5=Shyam S.\|last6=Neishaboori\|first6=Nastaran\|last7=Roy\|first7=Mohana\|last8=Schroers-Martin\|first8=Joe\|last9=Charville\|first9=Gregory W.\|date=2020-03-01\|title=Novel IRF8 and PD-L1 molecular aberrations in systemic EBV-positive T-cell lymphoma of childhood\|url=https://www.sciencedirect.com/science/article/pii/S2214330020300055\|journal=Human Pathology: Case Reports\|volume=19\|pages=200356\|doi=10.1016/j.ehpc.2020.200356\|issn=2214-3300}}</ref><ref name=":2">{{Cite journal\|last=Asmussen\|first=Anders\|last2=Quintanilla-Martinez\|first2=Leticia\|last3=Larsen\|first3=Martin\|last4=Fagerberg\|first4=Christina\|last5=Bækvad-Hansen\|first5=Marie\|last6=Juul\|first6=Maja Bech\|last7=Rewers\|first7=Kate\|last8=Raaschou-Jensen\|first8=Klas\|last9=Barnkob\|first9=Mike Bogetofte\|date=2024-01\|title=Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case\|url=https://pubmed.ncbi.nlm.nih.gov/37871127\|journal=Leukemia & Lymphoma\|volume=65\|issue=1\|pages=118–122\|doi=10.1080/10428194.2023.2264425\|issn=1029-2403\|pmid=37871127}}</ref>		* Somatic mutations have been reported; however, consistent/recurrent mutations are not well-described.<ref name=":10" /><ref>{{Cite journal\|last=Saleem\|first=Atif\|last2=Joshi\|first2=Rohan\|last3=Lei\|first3=Li\|last4=Lezama\|first4=Lhara\|last5=Raghavan\|first5=Shyam S.\|last6=Neishaboori\|first6=Nastaran\|last7=Roy\|first7=Mohana\|last8=Schroers-Martin\|first8=Joe\|last9=Charville\|first9=Gregory W.\|date=2020-03-01\|title=Novel IRF8 and PD-L1 molecular aberrations in systemic EBV-positive T-cell lymphoma of childhood\|url=https://www.sciencedirect.com/science/article/pii/S2214330020300055\|journal=Human Pathology: Case Reports\|volume=19\|pages=200356\|doi=10.1016/j.ehpc.2020.200356\|issn=2214-3300}}</ref><ref name=":2">{{Cite journal\|last=Asmussen\|first=Anders\|last2=Quintanilla-Martinez\|first2=Leticia\|last3=Larsen\|first3=Martin\|last4=Fagerberg\|first4=Christina\|last5=Bækvad-Hansen\|first5=Marie\|last6=Juul\|first6=Maja Bech\|last7=Rewers\|first7=Kate\|last8=Raaschou-Jensen\|first8=Klas\|last9=Barnkob\|first9=Mike Bogetofte\|date=2024-01\|title=Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case\|url=https://pubmed.ncbi.nlm.nih.gov/37871127\|journal=Leukemia & Lymphoma\|volume=65\|issue=1\|pages=118–122\|doi=10.1080/10428194.2023.2264425\|issn=1029-2403\|pmid=37871127}}</ref>
	** ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref name=":2" />		** ''FYN'' mutations have been reported in two cases <ref name=":10" /><ref name=":2" />
	** Mutations in ''KMT2D'', ''MFHAS1'', ''STAT3'', ''EP300'', ''ITPKB'', ''DDX3X'', ''NOTCH1'', ''NOTCH2'', ''TET2~~'', and ''STAT3~~'' (amongst others) have also been reported<ref>{{Cite journal\|last=Gao\|first=Li-Min\|last2=Zhao\|first2=Sha\|last3=Zhang\|first3=Wen-Yan\|last4=Wang\|first4=Mi\|last5=Li\|first5=Hui-Fang\|last6=Lizaso\|first6=Anle\|last7=Liu\|first7=Wei-Ping\|date=2019\|title=Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders\|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC6783120/\|journal=Cancer Biology & Therapy\|volume=20\|issue=10\|pages=1319–1327\|doi=10.1080/15384047.2019.1638670\|issn=1555-8576\|pmc=6783120\|pmid=31311407}}</ref>		** Mutations in ''KMT2D'', ''MFHAS1'', ''STAT3'', ''EP300'', ''ITPKB'', ''DDX3X'', ''NOTCH1'', ''NOTCH2'', and ''TET2'' (amongst others) have also been reported<ref>{{Cite journal\|last=Gao\|first=Li-Min\|last2=Zhao\|first2=Sha\|last3=Zhang\|first3=Wen-Yan\|last4=Wang\|first4=Mi\|last5=Li\|first5=Hui-Fang\|last6=Lizaso\|first6=Anle\|last7=Liu\|first7=Wei-Ping\|date=2019\|title=Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders\|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC6783120/\|journal=Cancer Biology & Therapy\|volume=20\|issue=10\|pages=1319–1327\|doi=10.1080/15384047.2019.1638670\|issn=1555-8576\|pmc=6783120\|pmid=31311407}}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 138:		Line 138:
	== Genetic Diagnostic Testing Methods ==		== Genetic Diagnostic Testing Methods ==

	* WHO 5th edition ''~~essential~~'' diagnostic criteria ~~include:~~<ref name=":3" /><ref name=":6" />		* In the WHO 5th edition, clonal TCR-gene rearrangements are included as ''desirable'' diagnostic criteria for the diagnosis of SEBVTCL of childhood<ref name=":3" /><ref name=":6" />
	** Acute presentation with fever and systemic symptoms
	** Multiorgan infiltration by atypical T-cells
	** EBV-positivity
	** Exclusion of known immunodeficiency

	* WHO 5th edition ''desirable'' diagnostic criteria include:<ref name=":3" /><ref name=":6" />
	** Clonal TCR-gene rearrangement
	** Hemophagocytic lymphohistiocytosis (HLH)
	** Hepatosplenomegaly
	* Differential Diagnosis with EBV-positive HLH is challenging		* Differential Diagnosis with EBV-positive HLH is challenging
	** TCR-gene rearrangements and aberrant T-cell phenotypes can be seen in both SEBVTCL of childhood and EBV-positive HLH		** TCR-gene rearrangements and aberrant T-cell phenotypes can be seen in both SEBVTCL of childhood and EBV-positive HLH

Karin.Miller: /* Primary Author(s)* */

2025-11-19T02:10:09Z

Primary Author(s)*

← Older revision		Revision as of 21:10, 18 November 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Systemic EBV-positive T-cell lymphoma of childhood}}		{{DISPLAYTITLE:Systemic EBV-positive T-cell lymphoma of childhood}}
	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	~~{{Under Construction}}~~

	<blockquote class="blockedit">{{Box-round\|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Systemic EBV-Positive T-cell Lymphoma of Childhood]].
	~~}}</blockquote>~~

	<span style="color:#0070C0">(General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)</span>

	==Primary Author(s)*==		==Primary Author(s)*==

Karin.Miller at 02:09, 19 November 2025

2025-11-19T02:09:08Z

← Older revision		Revision as of 21:09, 18 November 2025
Line 173:		Line 173:
	== Links ==		== Links ==
	[[HAEM4:EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]]<center><center>		[[HAEM4:EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]]<center><center>




Line 178:		Line 180:

	== References ==		== References ==
			<center><center>
	<center><center>		<center><center>
	<center><references />		<center><references />